PropertyValue
?:abstract
  • The Miller Fisher syndrome (MFS) is classified as a variant of the Guillain–Barré syndrome (GBS), accounting for 5‐25% of all GBS cases. Since the coronavirus disease‐2019 (COVID‐19) outbreak, increasing evidence of the neurologic manifestations of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, affecting both central and peripheral nervous system, has been described. Here we report the clinical course, detailed cerebrospinal fluid (CSF) profile including CSF/blood antibody status, and neurochemical parameters of a case with a typical clinical presentation of MFS after being tested positive for SARS‐CoV‐2 infection.
?:creator
?:doi
  • 10.1111/ene.14473
?:doi
?:journal
  • Eur_J_Neurol
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/186c93037b0bacc3ddc0270e95c37384fb5fde0a.json
?:pmcid
?:pmid
?:pmid
  • 32781484.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • Miller‐Fisher syndrome after COVID‐19: neurochemical markers as an early sign of nervous system involvement
?:type
?:year
  • 2020-08-11

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/7n42u6pw>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/7n42u6pw>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all